Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and ER-Negative PR-Negative HER2-Negative Breast Cancer

imatinib mesylate has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
ElShamy, WM; Koziol, J; Ryan, D1
Chang, JC; Keri, RA; Morrison, CD; Schiemann, WP1
Blanchard, Z; El-Etriby, R; Ellipeddi, P; Elshamy, WM; Hernandez, B; Isokpehi, R; Lage, JM; McKinney, S; Mullins, N; Zhang, X1
Pickard, MR; Williams, GT1

Other Studies

4 other study(ies) available for imatinib mesylate and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Targeting AXL and RAGE to prevent geminin overexpression-induced triple-negative breast cancer metastasis.
    Scientific reports, 2019, 12-16, Volume: 9, Issue:1

    Topics: Animals; Axl Receptor Tyrosine Kinase; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Polarity; Female; Geminin; Humans; Imatinib Mesylate; Macrophage Activation; Macrophages; Mesenchymal Stem Cells; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Proto-Oncogene Proteins; Receptor for Advanced Glycation End Products; Receptor Protein-Tyrosine Kinases; S100 Calcium-Binding Protein A4; Triple Negative Breast Neoplasms

2019
Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.
    Cell death & disease, 2017, 06-29, Volume: 8, Issue:6

    Topics: 14-3-3 Proteins; Apoptosis; Cell Cycle Proteins; Cell Proliferation; Cytoplasm; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; MCF-7 Cells; Multiprotein Complexes; Mutant Proteins; Protein Binding; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53

2017
Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative.
    PloS one, 2014, Volume: 9, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Female; Geminin; Humans; Imatinib Mesylate; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Triple Negative Breast Neoplasms

2014
Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy.
    Breast cancer research and treatment, 2014, Volume: 145, Issue:2

    Topics: Apoptosis; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; MCF-7 Cells; Morpholines; Piperazines; Pyrimidines; RNA, Long Noncoding; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms

2014